The effect of N-Acetylcysteine on COVID-19
Phase 3
- Conditions
- aboratory confirmed COVID-19.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20200509047364N3
- Lead Sponsor
- Bandare-abbas University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
All COVID-19 patients whose disease has been confirmed by the PCR test for SARS-Cov-2.
Having one of the criteria for severe COVID-19 disease includes tachypnea (respiration rate> 30 per minute), hypoxemia (O2 = saturation, arterial oxygen partial pressure ratio <300), pulmonary infiltration (> 50% of lung area during 24 48 h), LDH> 245 U / l, Progressive lymphopenia.
Hospitalized in the intensive care unit.
Signing the written consent of the study participant.
Exclusion Criteria
Known allergy or hypersensitivity to N-Acetylcysteine.
Pregnancy
The participant refused to participate in the continuation of the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient's clinical condition. Timepoint: At the time of admission to the hospital (Before starting the intervention) and on the 14th day of hospitalization or the day of discharge. Method of measurement: Clinical examinations.;Length of Intensive Care Unit admission. Timepoint: At the time of admission to the hospital (Before starting the intervention) and on the 14th day of hospitalization or the day of discharge. Method of measurement: Record patient information.
- Secondary Outcome Measures
Name Time Method